The Biology of Aging Is Not What You Think: 9 Hallmarks Explained

01 Aging Is a Disease

The foundational insight of modern longevity science is that aging isn't an inevitable decline — it's a set of biological processes that can be measured, targeted, and potentially reversed. The 9 hallmarks framework, published in 2013 and updated in 2023, identifies the cellular and molecular changes that drive aging. Each hallmark is a potential intervention point. The chart above shows where clinical trial investment is flowing — heavily toward cellular senescence and mitochondrial health.

02 Senolytics: Killing Zombie Cells

Cellular senescence is the #1 target in longevity research. Senescent cells stop dividing but don't die — they accumulate with age and secrete inflammatory molecules that damage surrounding tissue. They're 'zombie cells.' Senolytics are drugs that selectively kill senescent cells. The first human trials (dasatinib + quercetin) showed improved physical function in patients with diabetic kidney disease. Over 28 clinical trials are now testing senolytics for conditions from osteoarthritis to Alzheimer's.

03 Epigenetic Reprogramming

The most ambitious approach is epigenetic reprogramming — using Yamanaka factors to 'reset' cells to a younger state. In mice, this has extended lifespan by 25%. In humans, it's being tested in clinical trials for vision restoration (the OSK trial) and cardiovascular regeneration. The risk: if you push reprogramming too far, cells lose their identity entirely — they become stem cells, which can form tumors. The challenge is finding the sweet spot: enough reprogramming to rejuvenate, not enough to dedifferentiate.